Lung cancer combo trial ends early after enrolling just 5 patients
Disease control
Terminated
This study tested a new drug (HBI-8000) combined with an existing immunotherapy (pembrolizumab) in adults with advanced non-small cell lung cancer. The goal was to see if the combination was safe and tolerable. Only 5 people took part before the study was stopped early.
Phase: PHASE2 • Sponsor: HUYABIO International, LLC. • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC